

Brian Lee Claggett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4414334/publications.pdf>

Version: 2024-02-01

274
papers

22,106
citations

12303

69
h-index

10424

139
g-index

300
all docs

300
docs citations

300
times ranked

20044
citing authors

#	ARTICLE	IF	CITATIONS
1	Excess mortality in solid organ transplant recipients hospitalized with COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. <i>Clinical Transplantation</i> , 2022, 36, e14492.	0.8	33
2	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	3.0	59
3	Application of Optical Coherence Tomography Angiography Macular Analysis for Systemic Hypertension. A Systematic Review and Meta-analysis. <i>American Journal of Hypertension</i> , 2022, 35, 356-364.	1.0	10
4	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
5	Behind the Scenes of TOPCAT “Bending to Inform.”, 2022, 1, .		8
6	<scp>Angiotensin-“neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
7	Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 355-368.	1.2	24
8	Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2022, 10, 119-128.	1.9	15
9	Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2022, , e021715.	1.6	4
10	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. <i>Circulation</i> , 2022, 145, 1592-1604.	1.6	54
11	Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older Adults. <i>Journal of the American Heart Association</i> , 2022, 11, e022308.	1.6	5
12	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 336-346.	1.9	18
13	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	1.6	5
14	Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 1128-1136.	0.7	2
15	Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks. <i>JAMA Cardiology</i> , 2022, 7, 450.	3.0	17
16	Association of Left Atrial Structure and Function With Heart Failure in Older Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1549-1561.	1.2	38
17	Left atrial inflow propagation velocity derived by color M-mode Doppler in acute heart failure. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 2155-2165.	0.2	0
18	Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. <i>JAMA Cardiology</i> , 2022, 7, 623.	3.0	23

#	ARTICLE	IF	CITATIONS
19	Improved survival of left ventricular assist device carriers in <sc>Europe</sc> according to implantation eras: results from the <sc>PCHF&VAD</sc> registry. European Journal of Heart Failure, 2022, 24, 1305-1315.	2.9	10
20	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC&NCS. Journal of the American Heart Association, 2022, 11, e024292.	1.6	4
21	Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. BMJ Open, 2022, 12, e059994.	0.8	17
22	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .		10
23	Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. Diabetes Care, 2022, 45, 2152-2155.	4.3	3
24	Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn&TM's Disease. Inflammatory Bowel Diseases, 2021, 27, 677-685.	0.9	5
25	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	3.8	65
26	Cardiovascular and Renal Outcomes of&Mineralocorticoid Receptor Antagonist&Use in PARAGON-HF. JACC: Heart Failure, 2021, 9, 13-24.	1.9	22
27	Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. Circulation, 2021, 143, 761-763.	1.6	118
28	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. Hypertension, 2021, 77, 546-556.	1.3	26
29	Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 2021, 8, 1784-1795.	1.4	7
30	Spironolactone in Patients With Heart&Failure, Preserved Ejection Fraction, and Worsening Renal Function. Journal of the American College of Cardiology, 2021, 77, 1211-1221.	1.2	19
31	Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study. Circulation: Heart Failure, 2021, 14, e007891.	1.6	6
32	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	1.6	13
33	Temporal variations in the severity of COVID-19 illness by race and ethnicity. BMJ Nutrition, Prevention and Health, 2021, 4, 166-173.	1.9	3
34	Prospective ARNI vs. ACE inhibitor trial to Determlne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE&MI): design and baseline characteristics. European Journal of Heart Failure, 2021, 23, 1040-1048.	2.9	70
35	Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. JAMA Cardiology, 2021, 6, 509.	3.0	16
36	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (<sc>COSMIC</sc>&HF</sc>). European Journal of Heart Failure, 2021, 23, 1052-1056.	2.9	10

#	ARTICLE	IF	CITATIONS
37	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. JACC: Heart Failure, 2021, 9, 386-397.	1.9	11
38	Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy. American Journal of Gastroenterology, 2021, 116, 1638-1645.	0.2	12
39	A-lines and B-lines in patients with acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 909-917.	0.4	6
40	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	2.9	195
41	Influence of Study Discontinuation during the Run-in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGON-HF Trial. European Journal of Heart Failure, 2021, , .	2.9	5
42	Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. European Journal of Heart Failure, 2021, 23, 1290-1295.	2.9	19
43	Heart failure associated with imported malaria: a nationwide Danish cohort study. ESC Heart Failure, 2021, 8, 3521-3529.	1.4	9
44	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	3.0	12
45	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. Circulation, 2021, 144, 177-179.	1.6	20
46	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. Journal of Cardiac Failure, 2021, 27, 1382-1392.	0.7	3
47	Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 335, 59-65.	0.8	2
48	Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. Circulation, 2021, 144, e70-e91.	1.6	36
49	Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. Journal of the American College of Cardiology, 2021, 78, 89-91.	1.2	10
50	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019545.	1.6	29
51	Response to Cheng et al.. American Journal of Gastroenterology, 2021, Publish Ahead of Print, .	0.2	0
52	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in AHFpEF. JACC: Heart Failure, 2021, 9, 627-635.	1.9	21
53	Associations of Insulin Resistance With Systolic and Diastolic Blood Pressure: A Study From the HCHS/SOL. Hypertension, 2021, 78, 716-725.	1.3	12
54	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008293.	1.6	18

#	ARTICLE	IF	CITATIONS
55	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. <i>Statistics in Medicine</i> , 2021, 40, 6235-6242.	0.8	5
56	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
57	Angiotensin Receptor–Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	13.9	130
58	Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life. <i>Journal of the American Heart Association</i> , 2021, 10, e020094.	1.6	9
59	Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn’s Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1554-1561.	0.9	12
60	Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death. <i>Europace</i> , 2020, 22, 74-83.	0.7	13
61	Postsystolic shortening on echocardiography as a gateway to cardiac computed tomography in patients with suspected stable angina pectoris. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 309-316.	0.7	5
62	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
63	Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events. <i>International Journal of Cardiology</i> , 2020, 300, 237-244.	0.8	3
64	Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. <i>Circulation</i> , 2020, 142, 2080-2082.	1.6	168
65	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. <i>JACC: Heart Failure</i> , 2020, 8, 844-855.	1.9	56
66	Myocardial performance index is associated with cardiac computed tomography findings in patients with suspected coronary artery disease. <i>Echocardiography</i> , 2020, 37, 1741-1748.	0.3	0
67	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.	2.7	1
68	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. <i>Diabetes Care</i> , 2020, 43, 2226-2233.	4.3	36
69	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e008007.	1.6	10
70	Associations Between Depressive Symptoms and HFrEF-Related Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 1009-1020.	1.9	19
71	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
72	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1662-1671.	2.9	33

#	ARTICLE	IF	CITATIONS
73	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. <i>Hypertension</i> , 2020, 76, 808-818.	1.3	20
74	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020, 22, 1133-1143.	2.9	16
75	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 315-322.	1.8	43
76	Body mass index and BÆlines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1201-1209.	1.4	17
77	Quantification of pleural effusions on thoracic ultrasound in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 513-521.	0.4	14
78	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. <i>PLoS Medicine</i> , 2020, 17, e1003361.	3.9	7
79	Title is missing!. , 2020, 17, e1003361.		0
80	Title is missing!. , 2020, 17, e1003361.		0
81	Title is missing!. , 2020, 17, e1003361.		0
82	Title is missing!. , 2020, 17, e1003361.		0
83	Title is missing!. , 2020, 17, e1003361.		0
84	Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. <i>Heart</i> , 2019, 105, 34-41.	1.2	32
85	Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 387-397.	0.8	5
86	Cardiac implantable electronic devices with a defibrillator component and allÆcause mortality in left ventricular assist device carriers: results from the PCHFÆVAD registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1129-1141.	2.9	27
87	SEX AND RACE DIFFERENCES IN CIRCULATING LEVELS OF NATRIURETIC PEPTIDE CONCENTRATIONS AND THE ASSOCIATION WITH INCIDENT HEART FAILURE IN THE COMMUNITY: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 911.	1.2	0
88	Impact of Malnutrition Using Geriatric Nutritional Risk Index in HeartÆFailure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 664-675.	1.9	68
89	CAD is a Risk Factor for Heart Failure with Preserved Ejection Fraction: The ARIC Study. <i>Journal of Cardiac Failure</i> , 2019, 25, S93.	0.7	1
90	Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 1203.	3.0	33

#	ARTICLE	IF	CITATIONS
91	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. <i>JAMA Cardiology</i> , 2019, 4, 997.	3.0	38
92	Angiotensinâ€Nepirylsin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
93	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74
94	QuaLVAD Instrument: A New Measure of Quality of Life in Patients with a Left Ventricular Assist Device (LVAD). <i>Journal of Cardiac Failure</i> , 2019, 25, S156.	0.7	1
95	Lung Ultrasound in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 849-858.	1.9	116
96	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1199-1208.	2.2	83
97	Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction. <i>JAMA Network Open</i> , 2019, 2, e195321.	2.8	20
98	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	1.6	21
99	UTILITY OF BASELINE AND FOLLOW-UP CARDIOVASCULAR PHYSICAL EXAMS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: TOPCAT. <i>Journal of the American College of Cardiology</i> , 2019, 73, 712.	1.2	0
100	Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 483-490.	2.1	9
101	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.	1.2	139
102	Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 363.	3.0	97
103	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis. <i>JAMA Cardiology</i> , 2019, 4, 466.	3.0	68
104	Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. <i>JAMA Surgery</i> , 2019, 154, 466.	2.2	1
105	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 795-806.	1.2	173
106	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	2.9	129
107	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2858-2873.	1.2	138
108	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	1.9	6

#	ARTICLE	IF	CITATIONS
109	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019, 21, 1571-1579.	2.9	44
110	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019, 7, 25-32.	1.9	51
111	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	2.1	18
112	HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC Study. <i>Hypertension</i> , 2019, 73, 68-74.	1.3	7
113	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , 2019, 139, 422-423.	1.6	0
114	The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. <i>International Journal of Cardiology</i> , 2019, 284, 42-49.	0.8	19
115	Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2019, 21, 74-85.	2.9	175
116	Influenza Vaccine in Heart Failure. <i>Circulation</i> , 2019, 139, 575-586.	1.6	114
117	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin in Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	0.7	21
118	Towards personalized therapy for multiple sclerosis: limitations of observational data. <i>Brain</i> , 2018, 141, e38-e38.	3.7	8
119	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 547-554.	5.5	124
120	When the VEST Does Not Fit. <i>Circulation: Heart Failure</i> , 2018, 11, e005116.	1.6	2
121	Adiposity, body composition and ventricular arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2018, 20, 1191-1201.	2.9	34
122	Renal Effects and Associated Outcomes During Angiotensin-Nepilysin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 489-498.	1.9	272
123	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	1.6	55
124	Defining Study Outcomes That Better Reflect Individual Response to Treatment. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 258-262.	1.1	4
125	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	2.9	295
126	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2018, 3, 200.	3.0	41

#	ARTICLE	IF	CITATIONS
127	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018, 31, 407-414.	1.0	26
128	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018, 138, 570-577.	1.6	66
129	Lack of Association Between Heart Failure and Incident Cancer. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1501-1510.	1.2	49
130	Widening Racial Differences in Risks for Coronary Heart Disease. <i>Circulation</i> , 2018, 137, 1195-1197.	1.6	24
131	Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. <i>JAMA Cardiology</i> , 2018, 3, 357.	3.0	22
132	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 564-569.	1.9	43
133	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004457.	1.6	31
134	Trajectories of Blood Pressure Elevation Preceding Hypertension Onset. <i>JAMA Cardiology</i> , 2018, 3, 427.	3.0	25
135	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320.	0.7	49
136	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 815-816.	2.9	5
137	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , 2018, 131, 165-172.	0.6	33
138	Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. <i>European Journal of Heart Failure</i> , 2018, 20, 1106-1114.	2.9	45
139	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALITUDE trial. <i>Diabetologia</i> , 2018, 61, 581-588.	2.9	13
140	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	2.9	52
141	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 483-490.	2.9	28
142	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-9.	1.0	26
143	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005288.	1.6	35
144	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 1599-1601.	1.6	28

#	ARTICLE	IF	CITATIONS
145	Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1763-1773.	1.2	61
146	Caffeine Consumption and Mortality in Diabetes: An Analysis of NHANES 1999–2010. <i>Frontiers in Endocrinology</i> , 2018, 9, 547.	1.5	24
147	IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Nephilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	1.6	40
148	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1570-1577.	2.9	106
149	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1701-1709.	2.9	56
150	Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. <i>Statistics in Medicine</i> , 2018, 37, 3589-3598.	0.8	10
151	The Reply. <i>American Journal of Medicine</i> , 2018, 131, e349-e351.	0.6	1
152	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 689-697.	1.9	68
153	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Tj ETQq1 1 0,784314 rgBT /Ove 11, e004446.	1.6	58
154	Declining Lung Function and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1109-1122.	1.2	74
155	Sex as a predictor of response to cancer immunotherapy. <i>Lancet Oncology</i> , The, 2018, 19, e377.	5.1	2
156	Right Ventricular Function, Right Ventricular–Pulmonary Artery Coupling, and Heart Failure Risk in 4 US Communities. <i>JAMA Cardiology</i> , 2018, 3, 939.	3.0	71
157	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 155-164.	0.8	20
158	Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. <i>Lancet Public Health</i> , The, 2018, 3, e419-e428.	4.7	506
159	Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1617.	3.4	1
160	Visualization, Quantification, and Alignment of Spectral Drift in Population Scale Untargeted Metabolomics Data. <i>Analytical Chemistry</i> , 2017, 89, 1399-1404.	3.2	39
161	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload. <i>JACC: Heart Failure</i> , 2017, 5, 157-165.	1.9	38
162	Spirolactone Metabolites in TOPCAT – New Insights into Regional Variation. <i>New England Journal of Medicine</i> , 2017, 376, 1690-1692.	13.9	186

#	ARTICLE	IF	CITATIONS
163	Left atrial structure and function in cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1128-1137.	0.5	80
164	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	80
165	Racial Disparities in Risks of Stroke. <i>New England Journal of Medicine</i> , 2017, 376, 2089-2090.	13.9	24
166	Role of Bâ€Type Natriuretic Peptide and Nâ€Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
167	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 522-531.	2.1	15
168	An <i>NPPB</i> Promoter Polymorphism Associated With Elevated Nâ€Terminal proâ€Bâ€Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
169	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1043-1052.	2.9	34
170	Interaction Between Spironolactone and Natriuretic Peptides in Patients With HeartÂFailure and Preserved EjectionÂFraction. <i>JACC: Heart Failure</i> , 2017, 5, 241-252.	1.9	129
171	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> ,the, 2017, 5, 333-340.	5.5	258
172	Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults. <i>Circulation</i> , 2017, 135, 426-439.	1.6	99
173	Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	35
174	The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis. <i>Statistics in Biosciences</i> , 2017, 9, 284-297.	0.6	8
175	Ferritin levels and risk of heart failureâ€”the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2017, 19, 340-347.	2.9	51
176	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. <i>JAMA Oncology</i> , 2017, 3, 1692.	3.4	179
177	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 782-791.	1.9	21
178	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1560-1562.	1.6	15
179	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017, 5, 591-599.	1.9	12
180	Change in Hemoglobin Trajectory and Darbeopetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	1.4	8

#	ARTICLE	IF	CITATIONS
181	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	98
182	Sacubitril/valsartan in PARADIGM-HF – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 496.	5.5	0
183	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. <i>JAMA Cardiology</i> , 2017, 2, 79.	3.0	143
184	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.	2.9	34
185	Heart Failure Stages Among Older Adults in the Community. <i>Circulation</i> , 2017, 135, 224-240.	1.6	135
186	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 10, 233-242.	0.8	5
187	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 11, 1-7.	0.8	5
188	Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events. <i>Blood</i> , 2017, 130, 685-685.	0.6	3
189	Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (<scp>ARIC</scp>) Study. <i>European Journal of Heart Failure</i> , 2016, 18, 629-637.	2.9	38
190	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	24
191	Efficacy of Sacubitril/Valsartan Relative to Prior Decompensation. <i>JACC: Heart Failure</i> , 2016, 4, 816-822.	1.9	84
192	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002763.	1.6	224
193	Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2016, 37, 2544-2551.	1.0	33
194	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF – TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 537-544.	1.2	29
195	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1895-1902.	1.1	9
196	Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2016, 22, S65-S66.	0.7	0
197	Retinal Vessel Calibers in Predicting Long-Term Cardiovascular Outcomes. <i>Circulation</i> , 2016, 134, 1328-1338.	1.6	204
198	Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization. <i>Journal of Cardiac Failure</i> , 2016, 22, S24.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1228-1234.	2.9	173
200	On the Restricted Mean Survival Time Curve in Survival Analysis. <i>Biometrics</i> , 2016, 72, 215-221.	0.8	176
201	Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	59
202	Smoking and Cardiac Structure and Function in the Elderly. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004950.	1.3	55
203	Association between Baseline, and Changes in, Health-Related Quality of Life and Death and HF Hospitalization in PARADIGM-HF. <i>Journal of Cardiac Failure</i> , 2016, 22, S92.	0.7	0
204	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016, 68, 873-881.	2.1	28
205	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1238-1243.	2.9	56
206	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	52
207	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 666.	3.0	130
208	A Predictive Enrichment Procedure to Identify Potential Responders to a New Therapy for Randomized, Comparative Controlled Clinical Studies. <i>Biometrics</i> , 2016, 72, 877-887.	0.8	35
209	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016, 37, 455-462.	1.0	396
210	Prehypertension Is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study. <i>American Journal of Hypertension</i> , 2016, 29, 568-574.	1.0	46
211	Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2016, 374, 1094-1096.	13.9	55
212	Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004010.	1.3	21
213	A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 62, 873-878.	0.9	16
214	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002744.	1.6	130
215	Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. <i>Circulation: Heart Failure</i> , 2016, 9, e001937.	1.6	71
216	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	1.9	112

#	ARTICLE	IF	CITATIONS
217	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2016, 39, 677-685.	4.3	46
218	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016, 37, 466-472.	1.0	40
219	Response to Letter Regarding Article, "Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study." <i>Circulation: Heart Failure</i> , 2015, 8, 1010-1010.	1.6	0
220	A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. <i>Statistics in Medicine</i> , 2015, 34, 3680-3695.	0.8	23
221	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015, 36, 1990-1997.	1.0	335
222	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. <i>Annals of Internal Medicine</i> , 2015, 163, 127-134.	2.0	162
223	Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. <i>Biostatistics</i> , 2015, 16, 60-72.	0.9	38
224	Rationale, design, and baseline characteristics in Evaluation of Lixisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
225	Distinct neural representations of placebo and nocebo effects. <i>NeuroImage</i> , 2015, 112, 197-207.	2.1	91
226	Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2015, 66, 429-440.	2.1	29
227	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015, 373, 2289-2290.	13.9	92
228	Racial Differences in Circulating Natriuretic Peptide Levels: The Atherosclerosis Risk in Communities Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	53
229	The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans. <i>New England Journal of Medicine</i> , 2015, 372, 21-29.	13.9	202
230	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation</i> , 2015, 131, 34-42.	1.6	758
231	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2015, 36, 939-945.	1.0	82
232	Renal effects of the angiotensin receptor neprilysin inhibitor <sc>LCZ696</sc> in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 510-517.	2.9	153
233	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (<sc>VALIANT</sc>). <i>European Journal of Heart Failure</i> , 2015, 17, 301-312.	2.9	50
234	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015, 132, 402-414.	1.6	371

#	ARTICLE	IF	CITATIONS
235	Relationship Between Alcohol Consumption and Cardiac Structure and Function in the Elderly. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	36
236	Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. Journal of Cardiac Failure, 2015, 21, S9-S10.	0.7	6
237	Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort. Circulation, 2015, 132, 1329-1337.	1.6	137
238	Right Atrial Function in Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2015, 8, e003521; discussion e003521.	1.3	81
239	Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease. Circulation: Heart Failure, 2015, 8, 448-454.	1.6	68
240	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circulation: Heart Failure, 2015, 8, 1052-1058.	1.6	70
241	Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation, 2015, 132, 1979-1989.	1.6	54
242	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine, 2015, 373, 2247-2257.	13.9	1,856
243	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 2015, 36, 669-675.	1.0	62
244	Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. European Journal of Heart Failure, 2015, 17, 63-73.	2.9	20
245	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. Journal of Clinical Oncology, 2014, 32, 2380-2385.	0.8	501
246	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 2014, 35, 3442-3451.	1.0	78
247	Reply: The Association between Obstructive Sleep Apnea Severity and N-Terminal Pro-B-Type Natriuretic Peptide Levels in Women. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 869-870.	2.5	0
248	Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 1096-1103.	2.9	194
249	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 535-542.	2.9	184
250	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. Circulation: Heart Failure, 2014, 7, 895-902.	1.6	43
251	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 740-751.	1.6	218
252	Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist. Circulation: Heart Failure, 2014, 7, 573-579.	1.6	155

#	ARTICLE	IF	CITATIONS
253	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 372-381.	0.3	26
254	Spironolactone for Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2014, 370, 1383-1392.	13.9	1,993
255	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 447-456.	1.2	591
256	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <sc>LCZ696</sc>, in patients with heart failure with preserved ejection fraction: an analysis of the <sc>PARAMOUNT</sc> trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	2.9	67
257	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
258	Temporal Trends in the Population Attributable Risk for Cardiovascular Disease. <i>Circulation</i> , 2014, 130, 820-828.	1.6	135
259	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1535-1536.	1.2	0
260	Heart Failure Risk Across the Spectrum of Ankle-Brachial Index. <i>JACC: Heart Failure</i> , 2014, 2, 447-454.	1.9	46
261	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.	1.6	123
262	Meta-Analysis With Fixed, Unknown, Study-Specific Parameters. <i>Journal of the American Statistical Association</i> , 2014, 109, 1660-1671.	1.8	22
263	Insulin Resistance and Incident Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 531-536.	1.9	77
264	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , 2013, 77, 624-630.	0.5	49
265	Moving beyond our comfort zone. <i>European Heart Journal</i> , 2013, 34, 869-871.	1.0	10
266	Sleep Apnea Is Associated with Subclinical Myocardial Injury in the Community. The ARIC-SHHS Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1460-1465.	2.5	77
267	Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 970-976.	1.6	33
268	Differential Influence of Distinct Components of Increased Blood Pressure on Cardiovascular Outcomes. <i>Hypertension</i> , 2013, 62, 492-498.	1.3	11
269	Effectively Selecting a Target Population for a Future Comparative Study. <i>Journal of the American Statistical Association</i> , 2013, 108, 527-539.	1.8	123
270	Are All Placebo Effects Equal? Placebo Pills, Sham Acupuncture, Cue Conditioning and Their Association. <i>PLoS ONE</i> , 2013, 8, e67485.	1.1	78

#	ARTICLE	IF	CITATIONS
271	Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e19.	1.3	40
272	Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. <i>European Heart Journal</i> , 2012, 33, 1137-1141.	1.0	66
273	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 1174-1180.	0.5	70
274	Sa1620 A Novel Upper Gastrointestinal Bleeding Score (AIMS65) Is More Accurate Than the Modified Blatchford Score in Predicting Mortality and Rebleeding. <i>Gastrointestinal Endoscopy</i> , 2011, 73, AB225-AB226.	0.5	0